Trials / Unknown
UnknownNCT05273099
Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma
Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma: A Pilot Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (estimated)
- Sponsor
- Università degli Studi di Ferrara · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Endometrial carcinoma represents the most common gynaecological cancer and the sixth most frequent cancer among women worldwide. The 5-year survival of patients with stage I endometrial carcinoma is 75%-88% versus 50% for stage III or 15% for stage IV disease. Therefore, early detection could improve survival rates. Specifically, in the most prevalent, type 1 endometrial cancer develops from hyperplastic endometrium. The aim of the study was to evaluate the utility of cancer gene mutations from endometrial biopsies towards predicting synchronous or metachronous development of malignant lesions. The aim of the study was to evaluate whether endometrial biopsies could already carry mutations in cancer genes useful for predicting or anticipating subsequent cancer development
Conditions
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2023-03-01
- Completion
- 2023-12-01
- First posted
- 2022-03-10
- Last updated
- 2022-04-12
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05273099. Inclusion in this directory is not an endorsement.